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Timely detection of novel coronavirus (2019-nCoV) 
infection cases is crucial to interrupt the spread of this 
virus. We assessed the required expertise and capac-
ity for molecular detection of 2019-nCoV in specialised 
laboratories in 30 European Union/European Economic 
Area (EU/EEA) countries. Thirty-eight laboratories in 
24 EU/EEA countries had diagnostic tests available by 
29 January 2020. A coverage of all EU/EEA countries 
was expected by mid-February. Availability of prim-
ers/probes, positive controls and personnel were main 
implementation barriers.
In early January 2020, it became evident that a new 
pathogenic human coronavirus, provisionally named 
novel coronavirus (2019-nCoV), had emerged in China 
[1,2]. The virus is causing an outbreak, which started 
in the metropole Wuhan, but was seeded through trav-
ellers across China with ongoing secondary chains of 
transmission in a wider geographical area. As at 10 
February 2020, 40,553 confirmed cases including 910 
deaths have been reported worldwide with an increas-
ing number of cases being reported in Europe [3]. So 
far, instances of secondary spread from international 
travellers have been limited, but clusters of human-to-
human transmission have been reported involving per-
sons with close contact to confirmed cases [4]. A key 
knowledge gap is the efficiency of community trans-
mission of 2019-nCoV, including the contribution of 
mild or asymptomatic cases. On 30 January 2020, the 
Word Health Organization (WHO) declared the outbreak 
a public health emergency of international concern 
(PHEIC) because of these uncertainties, the ongoing 
seeding of the virus internationally, and the need for 
preparedness across the world in order to track and 
control the epidemic. WHO highlighted the crucial role 
of early detection of cases to interrupt virus spread and 
emphasised that countries need to put in place strong 
measures to detect and laboratory-confirm cases early 
[5]. Here, we assessed the required expertise and 
diagnostic capacity in specialised laboratories in 30 
European Union/European Economic Area (EU/EEA) 
countries.
Survey
A questionnaire was designed to assess the capac-
ity, quality and operational specifics related to 2019-
nCoV diagnostics, as well as barriers against their 
implementation in laboratories that are part of the 
European Centre for Disease Control and Prevention 
(ECDC)-associated European expert laboratory network 
for emerging viral diseases (EVD-LabNet) and/or the 
European Reference Laboratory Network for Human 
Influenza (ERLI-Net). The survey was sent on 22 January 
2020 to the Operational Contact Points representing 
81 laboratories in, among others, 30 EU/EEA coun-
tries. The survey subsequently closed on 29 January 
2020 (Figure 1). Where indicated, data were validated 
by individual email exchange with the laboratories to 
include one entry per laboratory. Entries from labora-
tories outside the EU/EEA and veterinary laboratories 
were omitted from analysis for this report. In total, the 
data provided by 47 laboratories in 30 EU/EEA coun-
tries were taken into account in this study.
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Capacity for novel coronavirus molecular 
diagnostics
At country level, 24 of 30 EU/EEA countries had already 
implemented molecular tests for 2019-nCoV while 
the laboratories in the remaining six countries had 
arranged to ship clinical specimens of suspected cases 
to a specialised laboratory abroad, while planning to 
implement assays between 30 January and 17 February 
2020. At the laboratory level, 38 of 47 responding labo-
ratories had implemented molecular diagnostics for 
2019-nCoV at survey submission, and eight of the nine 
remaining laboratories planned to have tests imple-
mented by mid-February 2020 (Figure 2). Nineteen lab-
oratories indicated to have capacity to perform whole 
genome sequencing on 2019-nCoV in clinical samples, 
while 15 laboratories could perform partial sequencing.
The laboratories were asked to indicate their weekly 
capacity for molecular testing for 2019-nCoV (Figure 
3). Overall, for all 38 laboratories with current capac-
ity this was indicated to be at a minimum of 8,275 
tests per week. The eight laboratories in the process 
of implementing molecular diagnostics would, all com-
bined, add a minimum capacity of 875 tests per week 
once this process would be complete. 
Expertise for coronavirus and other 
respiratory pathogens
Forty-five laboratories in 28 countries indicated having 
previous expertise in human coronavirus (HCoV) diag-
nostics. For two countries the two responding labora-
tories had no experience. Twenty-five laboratories in 
19 countries indicated having experience in molecular 
diagnostics for all six additional HCoVs (HCoV-HKU1, 
HCoV-OC43, HCoV-NL63, HCoV-229E, Middle East res-
piratory syndrome CoV and severe acute respiratory 
syndrome CoV) [6]. Forty-four laboratories in 29 coun-
tries performed differential testing for other common 
respiratory pathogens of viral and bacterial origin. 
Overall, the 47 survey respondents indicated their 
ability to process a wide range of respiratory sam-
ple types, including nasopharyngeal swabs (n = 38), 
Figure 1
Time-line with hallmark events of the first two months of the novel coronavirus (2019-nCoV) outbreak, December 2019–
January 2020
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bronchoalveolar lavage (n = 36), oropharyngeal swab 
(n = 34), nasopharyngeal aspirate (n = 34), sputum 
(n = 34), (endo) tracheal aspirate (n = 32) and nasal 
wash (n = 29). In addition, a number of respondents 
indicated that their laboratories could process biopsy 
materials (n = 28) and whole blood, plasma, serum 
(n = 28) for 2019-nCoV detection.
Implementation of molecular diagnostics 
for novel coronavirus
Biosafety level
For the biosafety-level (BSL) applied for inactivation of 
clinical samples suspected of 2019-nCoV, 22 laborato-
ries of the 47 EU/EEA laboratories indicated to do this 
at BSL2. Twenty-one laboratories indicated to do so at 
BSL3. Four laboratories indicated an intermediate level 
BSL2 + (BSL2 with extra precautions such as wearing a 
filtering face piece (FFP)2 mask). Different approaches 
were observed between laboratories within some 
countries.
Test specifics
As of 14 January 2020, protocols for RT-PCR of 2019-
nCoV are being published on the WHO website [7]. At 
survey closure (29 January 2020), the envelope (E)-gene 
screening test as published by Corman et al. [6,7], had 
been implemented by 35 laboratories and the confirma-
tory RNA-dependent RNA polymerase (RdRp)-gene test 
and nucleoprotein (N)-gene test by respectively 33 and 
21 laboratories. Sixteen laboratories indicated to have 
additional tests, i.e. in house tests (n = 5), pan-CoV 
tests (n = 12) or an assay based on Poon et al. (n = 1) [7]. 
Two laboratories indicated to base 2019-nCoV testing 
solely on previously published pan-CoV tests [8].
Figure 2
Status of availability of molecular diagnostics for novel coronavirus (2019-nCoV) in EU/EEA countries as at 29 January 
2020 (n = 46 laboratories)a
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EU/EEA: European Union/European Economic Area; 2019-nCoV: 2019 novel coronavirus.
a One laboratory of the 47 included in the current study did not indicate when its molecular diagnostics would be available.
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Level of specificity validation
Only 11 laboratories of the 38 laboratories that had 
implemented testing indicated having validated the 
specificity of the implemented test against the six addi-
tionally known HCoVs and other common respiratory 
pathogens. For 15 laboratories, specificity validation 
was still in progress at the time of data submission. 
Seven laboratories indicated to have only partially vali-
dated the implemented test(s) while five laboratories 
had not (yet) performed any validation. The question-
naire was send out before the first 2019-nCoV cases 
appeared in Europe (Figure 1) and positive clinical 
specimens were assumed to be not available to the 
European laboratories. Therefore, the level of valida-
tion for clinical sensitivity was not assessed.
Positive control
Three of 38 laboratories that had implemented diag-
nostics did the implementation without a positive con-
trol. Indicated sources for positive controls were the 
European Virus Archive (EVAg) (synthetic 2019-nCoV 
E-gene, SARS-CoV RNA) (n = 23) [9], or own stocks, i.e. 
SARS-HCoV RNA and/or synthetic RNA (n = 15).
Diagnostic challenges
The top three challenges that were experienced for test 
implementation were an initial lack of positive control, 
lack of personnel/time and a lack of primers and/or 
probes (Figure 4). Nine laboratories in eight countries 
indicated no obstacles.
Discussion
As at 10 February 2020, 37 confirmed 2019-nCoV cases 
were reported from eight European countries based 
on ECDC reporting and testing criteria [3,10]. Multiple 
modelling studies estimated the risk of 2019-nCoV 
introduction to Europe as high [11-14]. Pullano et al. 
indicated the United Kingdom, France and Germany as 
being at the highest risk, followed by Italy, Spain and 
the Netherlands [11]. Indeed, all but one country (the 
Netherlands) have reported cases. The study reported 
that the occurrence of 2019-nCoV importation from 
Beijing and Shanghai, both cities with high numbers of 
travellers to Europe, would likely lead to an even higher 
and widespread risk for Europe.
This rapid assessment of the readiness of EU/EEA labo-
ratories for molecular detection of 2019-nCoV demon-
strated a fast implementation of molecular diagnostics 
by the European specialised laboratory networks with 
a good geographical coverage for testing. Among both 
laboratory networks in this study, protocols were 
shared rapidly and there was an early availability of 
positive controls and CoV specificity panels via EVAg. 
Furthermore, the survey indicated a great willingness 
of laboratories to provide international diagnostic sup-
port [10] and to share sequences to contribute to the 
monitoring of virus evolution and trace transmission 
chains.
However, although the first protocols suggesting 
primer/probe sequences were available fast through 
the WHO website (Figure 1) and validation panels were 
made available through the EVAg portal soon after 
[6,7], the availability of primers, probes and posi-
tive controls were indicated as most important initial 
obstacles for test implementation. In addition, lack of 
sufficient personnel to implement and validate was a 
barrier, as had been observed in response to the Zika 
virus (ZIKV) outbreak in the Americas and the related 
PHEIC [15]. This suggests that the challenges faced by 
specialised laboratories when responding to emerging 
events are of structural nature.
Capacity-wise, the survey indicates that European 
specialised laboratories are prepared for the current 
situation, and suggests that a more sensitive case defi-
nition than currently in use [10,16] would not create an 
immediate bottleneck. However, it remains to be seen 
how realistic the estimates are, particularly in view of 
the coinciding seasonal epidemic peaks of other res-
piratory pathogens such as influenza viruses. This will 
depend on the epidemiological developments in the 
2019-nCoV outbreak and on whether the current world-
wide control strategy of containment with active case 
Figure 3
Diagnostic capacity of specialised laboratories with 
molecular tests available or forthcoming for novel 
coronavirus (2019-nCoV), EU/EEA, January 2020 (n = 46)a
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finding [5] will be sustained and the indicated labora-
tory capacity will suffice. If the outbreak turns into a 
pandemic, specialised laboratories’ efforts would refo-
cus to reference activities like confirmatory testing, 
laboratory surveillance including virus characterisa-
tion, provision of reference materials and advice, while 
general testing for 2019-nCoV would shift to first-line 
hospital laboratories that currently do not have this 
capacity. This would require a roll-out of tests from the 
specialised laboratories as was done during the 2009 
influenza A(H1N1) pandemic.
The survey showed that proper validation of specificity 
was lacking in a vast majority of the laboratories that 
had implemented testing while very few laboratories 
indicated to have implemented tests without availabil-
ity of a positive control. The important assessment of 
the clinical sensitivity of the implemented tests was not 
possible in this very early phase of laboratory response 
due to the, at the time, absence of positive clinical 
materials in Europe. The three laboratories without a 
positive control will also not have assessed the ana-
lytical sensitivity of their tests. The legal possibilities 
(General Data Protection Regulation; GDPR) for sharing 
and the willingness to share positive clinical material 
among the network laboratories now that the first 37 
cases have been confirmed in the EU/EEA will deter-
mine the speed with which laboratories can address 
the clinical sensitivity of their implemented tests while 
the number of cases in the EU/EEA is still limited.
To properly assess the actual capability of the labora-
tories to detect (sub)clinical 2019-nCoV cases and to 
provide directions for corrective actions, proficiency 
testing by external quality assessment (EQA) is essen-
tial and urgently needed. The importance of EQA was 
illustrated in the European ZIKV response where timely 
implementation was not matched by an overall good 
capability [17]. Forty of the 47 responding laborato-
ries in this study indicated that they will participate in 
such an assessment. Currently activities are ongoing 
to assess the actual capabilities within both laboratory 
networks by EQA.
In conclusion, while molecular testing for 2019-nCoV 
was quickly implemented in EU/EEA countries there is 
still room for improvement especially in the aspect of 
clinical validation of specificity and sensitivity, as could 
be expected considering the survey was taken in the 
very early phase of the laboratory response. Capability 
testing based on proficiency panels is needed.
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